Loading...
01/10 17:10
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates solid financial performance with increased revenues, net income, and EBITDA. Positive guidance, ongoing product launches, and strategic initiatives like M&A and plasma expansion further bolster growth prospects. While some uncertainties exist (e.g., CMV study specifics), the overall sentiment is positive, supported by strong financials and strategic plans.
Total Revenues (First 9 Months of 2025) $135.8 million, representing an 11% year-over-year increase. The growth was primarily due to increased sales of GLASSIA in ex-U.S. markets, increased sales in the distribution segment, and VARIZIG sales in the U.S. market.
Adjusted EBITDA (First 9 Months of 2025) $34.2 million, up 35% year-over-year, representing a 25% margin of revenues. This increase reflects the overall improvement in product sales mix and commercial scale.
Total Revenues (Third Quarter of 2025) $47 million, up 13% compared to $41.7 million in the third quarter of 2024. The increase was driven by the diversity of the product portfolio and increased sales of GLASSIA and VARIZIG.
Gross Profit and Gross Margins (Third Quarter of 2025) $19.8 million and 42%, compared to $17.2 million and 41% in the third quarter of 2024. The improvement is attributed to the continued improvement of product sales mix and commercial scale.
Gross Profit and Gross Margins (First 9 Months of 2025) $59.4 million and 44%, compared to $52.9 million and 43% in the first 9 months of 2024. The increase is in line with the overall improvement in product sales mix and commercial scale.
Operating Expenses (First 9 Months of 2025) $36.8 million, compared to $38 million in the first 9 months of 2024. The decrease is mainly related to a reduction in R&D expenses due to development project timing changes.
Net Income (Third Quarter of 2025) $5.3 million or $0.09 per diluted share, up 37% compared to the third quarter of 2024.
Net Income (First 9 Months of 2025) $16.6 million or $0.29 per diluted share, up 56% compared to the first 9 months of 2024.
Adjusted EBITDA (Third Quarter of 2025) $11.7 million, up 34% over the third quarter of 2024.
Cash Provided by Operations (First 9 Months of 2025) $17.9 million, contributing to a strong cash position of $72 million at the end of the quarter.
Anti-rabies immunoglobulin KEDRAB: Continued strong performance in the U.S. market through collaboration with Kedrion, with a firm commitment to minimum orders for 2025-2027. Sales are also growing in international markets such as Canada, Latin America, and Asia.
Anti-CMV immunoglobulin CYTOGAM: Initiated a comprehensive post-marketing research program, including the SHIELD study, to explore its benefits in CMV disease management for high-risk kidney transplant recipients.
Biosimilar products: Following the launch of the first biosimilar in Israel, two additional biosimilars are set to launch soon, with a pipeline for future launches. Expected to generate $15-$20 million in annual sales within five years.
Inhaled alpha-1 antitrypsin therapy (InnovAATe trial): Ongoing Phase III clinical trial with an interim futility analysis expected by the end of the quarter.
GLASSIA: Increased sales in ex-U.S. markets, particularly in Latin America and the CIS region. Continues to generate royalty income in the U.S. and Canada through Takeda.
Plasma collection centers: Ramping up operations at Houston and San Antonio centers, with FDA approval for Houston and expected approval for San Antonio in early 2026. Each center is projected to generate $8-$10 million annually at full capacity.
Revenue growth: Total revenues for the first 9 months of 2025 were $135.8 million, an 11% increase year-over-year. Adjusted EBITDA grew by 35% to $34.2 million.
Cost management: Operating expenses decreased slightly due to reduced R&D expenses, contributing to improved profitability.
Business development and M&A: Active due diligence on potential commercial targets, with plans for in-licensing, collaborations, and M&A transactions in early 2026 to enhance the product portfolio.
Regulatory Approvals: The San Antonio plasma collection site is awaiting FDA approval, expected in early 2026. Additionally, subsequent inspections and approvals from the European Medicine Agency (EMA) are required for both plasma collection sites. Delays or failure in obtaining these approvals could impact operations and revenue generation.
Product-Specific Risks: CYTOGAM's post-marketing research program aims to demonstrate its advantages in CMV disease management. However, the lack of recent clinical data on CYTOGAM's benefits poses a challenge to its market adoption and growth potential.
Royalty Income Decline: GLASSIA's royalty income has declined due to a reduction in the royalty rate, which could impact overall revenue growth despite increased sales in other areas.
Strategic Execution Risks: The company is conducting due diligence on potential M&A and in-licensing opportunities. Failure to secure compelling transactions or integrate them effectively could hinder long-term growth objectives.
Plasma Collection Operations: The Houston and San Antonio plasma centers are ramping up operations, but achieving full capacity and securing long-term sales agreements for normal source plasma remain critical challenges.
Annual Revenue Guidance: Kamada reiterates its annual revenue guidance of $178 million to $182 million for 2025, representing double-digit growth over 2024 results.
Adjusted EBITDA Guidance: The company maintains its adjusted EBITDA guidance of $40 million to $44 million for 2025, reflecting significant profitability growth.
Biosimilar Product Launches: Kamada plans to launch two additional biosimilars in the coming months, with expectations of annual sales of $15 million to $20 million within the next five years.
Business Development and M&A: The company anticipates securing in-licensing, collaboration, and/or M&A transactions in early 2026 to enhance its portfolio and support long-term growth.
Plasma Collection Centers: Kamada's Houston plasma center has received FDA approval, and the San Antonio center is expected to follow in early 2026. Each center is projected to generate $8 million to $10 million in annual revenues at full capacity.
Phase III InnovAATe Clinical Trial: The company is advancing its pivotal Phase III InnovAATe clinical trial for inhaled alpha-1 antitrypsin therapy, with interim futility analysis results expected by the end of Q4 2025.
The selected topic was not discussed during the call.
The earnings call indicates solid financial performance with increased revenues, net income, and EBITDA. Positive guidance, ongoing product launches, and strategic initiatives like M&A and plasma expansion further bolster growth prospects. While some uncertainties exist (e.g., CMV study specifics), the overall sentiment is positive, supported by strong financials and strategic plans.
The earnings call reflects strong financial metrics, with revenue and net income growth, disciplined expense management, and a solid cash position. The company's strategic initiatives, including biosimilar launches and plasma collection expansion, are promising. While some analyst concerns about competitive landscape and vague responses on funding were noted, the overall sentiment remains positive. The reiteration of 2025 guidance and a robust product portfolio further support a positive outlook. Given the lack of market cap data, a moderate positive reaction is expected, likely resulting in a 2% to 8% stock price increase.
Kamada's earnings call highlights strong financial performance with a 17% revenue increase and improved margins. The expansion of plasma collection centers and optimistic 2025 guidance further bolster sentiment. The special dividend reflects confidence in business prospects, positively impacting shareholder sentiment. Although there are regulatory and competitive risks, the company's proactive approach in clinical trials and product portfolio diversification mitigates these concerns. The Q&A section reveals management's confidence despite uncertainties, contributing to a positive outlook. Overall, the earnings call suggests a positive stock price movement in the coming weeks.
The earnings call highlighted strong financial performance with revenue and EBITDA growth, improved margins, and increased net income. The reaffirmed revenue and EBITDA guidance for 2025 indicates confidence in future growth. Regulatory, competitive, and supply chain risks were acknowledged but did not overshadow the positive outlook. The special dividend reflects confidence in business prospects. The Q&A session revealed ongoing clinical progress and no significant negative impact from tariffs or NIH spending. Overall, the positive financial results and optimistic guidance suggest a positive stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
